Neuroscience
Today's Yale Daily News includes an article about last week's announcement about the initiative to examine imaging technologies in the diagnosis of Alzheimer disease. The article is interesting to read of itself, but also because it touches briefly upon the concern of the neuropsychological community about the important role of neuropsychological assessment in the assessment of the cognitive changes that are diagnostically relevant:
[ ... Read the full article ... ]
- Alzheimer's Disease: Phase Ii Gammagard Findings
A report from the Alzheimer's Association International Conference (AAIC) in Vancouver: Alzheimer's drug IVIg could halt sufferers' decline Trial involving 16 patients excites scientists by suggesting treatment prevented deterioration of memory...
- Fda: Alzheimer's, Amyvid (florbetapir)
From MedPage Today: FDA Puts Early Alzheimer's Test on Hold By Peggy Peck, Executive Editor MedPage Today Published: March 18, 2011 [snip] "The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Bondi MW, Jak AJ, Delano-Wood L, Jacobson MW, Delis DC, & Salmon DP. Neuropsychological Contributions to the Early Identification of Alzheimer's Disease. Neuropsychological Review. 2008 Mar 18. A wealth of evidence demonstrates that a prodromal period...
- Abstract Of The Day: Structural Mri Markers
den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, & Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Archives of General Psychiatry. 2006 Jan;...
- Imaging Alzheimer Disease
From a press release by the National Institute on Aging:National Institute on Aging, Industry Launch Partnership, 60 Million Dollar Alzheimer’s Disease Neuroimaging Initiative Wednesday, October 13, 2004, 10 a.m. ET Contact: Vicky Cahan...
Neuroscience
Imaging Alzheimer Disease - Part 2
Today's Yale Daily News includes an article about last week's announcement about the initiative to examine imaging technologies in the diagnosis of Alzheimer disease. The article is interesting to read of itself, but also because it touches briefly upon the concern of the neuropsychological community about the important role of neuropsychological assessment in the assessment of the cognitive changes that are diagnostically relevant:
Scientists seek earlier Alzheimer's diagnoses
BY ALBERTO MASLIAH
Contributing Reporter
Yale Daily News
Published Monday, October 18, 2004
[snip]
Currently, neuropsychological assessment is the most widely used instrument for neurocognitive ability and its deterioration. The introduction of imaging analysis used to differentiate which patients with mild cognitive impairment will progress to Alzheimer's and how far an Alzheimer's patient has progressed is relatively new.
Within the field of neuropsychology, there is controversy about whether this initiative's focus on imaging rather than currently used assessments will be effective.
"The way I see it, is that this is not meant to substitute [for] neuropsychological testing, but it should only be additive in terms of identifying who will progress to [Alzheimer's] and will only be beneficial to the patient," said Effie Mitsis, a neuropsychologist working with van Dyck.
[snip]
[ ... Read the full article ... ]
- Alzheimer's Disease: Phase Ii Gammagard Findings
A report from the Alzheimer's Association International Conference (AAIC) in Vancouver: Alzheimer's drug IVIg could halt sufferers' decline Trial involving 16 patients excites scientists by suggesting treatment prevented deterioration of memory...
- Fda: Alzheimer's, Amyvid (florbetapir)
From MedPage Today: FDA Puts Early Alzheimer's Test on Hold By Peggy Peck, Executive Editor MedPage Today Published: March 18, 2011 [snip] "The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Bondi MW, Jak AJ, Delano-Wood L, Jacobson MW, Delis DC, & Salmon DP. Neuropsychological Contributions to the Early Identification of Alzheimer's Disease. Neuropsychological Review. 2008 Mar 18. A wealth of evidence demonstrates that a prodromal period...
- Abstract Of The Day: Structural Mri Markers
den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, & Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Archives of General Psychiatry. 2006 Jan;...
- Imaging Alzheimer Disease
From a press release by the National Institute on Aging:National Institute on Aging, Industry Launch Partnership, 60 Million Dollar Alzheimer’s Disease Neuroimaging Initiative Wednesday, October 13, 2004, 10 a.m. ET Contact: Vicky Cahan...